Teleflex Incorporated (TFX) Director George Babich, Jr. Sells 2,500 Shares

Teleflex Incorporated (NYSE:TFX) Director George Babich, Jr. sold 2,500 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $263.38, for a total value of $658,450.00. Following the transaction, the director now directly owns 10,583 shares of the company’s stock, valued at $2,787,350.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Teleflex Incorporated (TFX) traded up $9.38 during midday trading on Wednesday, reaching $272.31. The company had a trading volume of 344,509 shares, compared to its average volume of 243,209. Teleflex Incorporated has a 1 year low of $162.79 and a 1 year high of $272.46. The company has a quick ratio of 3.70, a current ratio of 4.72 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $12,250.00, a PE ratio of 49.15, a PEG ratio of 1.94 and a beta of 1.09.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 EPS for the quarter, beating the consensus estimate of $2.01 by $0.11. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The firm had revenue of $534.70 million during the quarter, compared to analysts’ expectations of $522.94 million. During the same period in the prior year, the firm posted $1.80 earnings per share. The business’s quarterly revenue was up 17.3% compared to the same quarter last year. sell-side analysts forecast that Teleflex Incorporated will post 8.36 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on the company. Morgan Stanley upped their price objective on Teleflex from $274.00 to $290.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. Stephens reissued a “buy” rating and set a $270.00 price target (up from $230.00) on shares of Teleflex in a research report on Monday, September 25th. Zacks Investment Research cut Teleflex from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. ValuEngine cut Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Piper Jaffray Companies started coverage on Teleflex in a research report on Friday, November 10th. They set an “overweight” rating and a $295.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $274.44.

Large investors have recently added to or reduced their stakes in the business. Clinton Group Inc. bought a new stake in Teleflex in the second quarter valued at approximately $325,000. Koch Industries Inc. raised its stake in Teleflex by 47,174.3% in the second quarter. Koch Industries Inc. now owns 959,669 shares of the medical technology company’s stock valued at $955,000 after buying an additional 957,639 shares during the period. Legal & General Group Plc raised its stake in Teleflex by 5.8% in the third quarter. Legal & General Group Plc now owns 90,332 shares of the medical technology company’s stock valued at $21,854,000 after buying an additional 4,929 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in Teleflex in the third quarter valued at approximately $955,000. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in Teleflex by 1.6% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 128,651 shares of the medical technology company’s stock valued at $31,130,000 after buying an additional 2,050 shares during the period. Hedge funds and other institutional investors own 89.29% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/17/teleflex-incorporated-tfx-director-george-babich-jr-sells-2500-shares.html.

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply